Medicinova INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

19 Feb 2025

MNOV

10-K: MediciNova Reports Annual Results for 2024, Highlights Progress in Clinical Development Programs

MediciNova's 2024 10-K filing details the company's ongoing clinical trials and financial status, emphasizing the development of MN-166 and MN-001 for various neurological and fibrotic disorders.

NASDAQ

15 Feb 2024

MNOV

Medicinova INC

10-K: MediciNova, Inc. Files 10-K Annual Report, Outlines Progress in Key Clinical Programs

MediciNova, Inc. released its 10-K annual report, detailing financial results and progress across its clinical development pipeline, with a focus on MN-166 and MN-001.